<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722809</url>
  </required_header>
  <id_info>
    <org_study_id>ZWETYENGA CRBFC 2020</org_study_id>
    <nct_id>NCT04722809</nct_id>
  </id_info>
  <brief_title>Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology</brief_title>
  <acronym>Botox</acronym>
  <official_title>Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bruxism is defined as a parafunction that consists of a clenching of the jaw and/or grinding&#xD;
      of the teeth. It can occur when an individual is sleeping or awake or it can be mixed.&#xD;
&#xD;
      Most often, it is primary or idiopathic bruxism, however when it is related to a cause it is&#xD;
      qualified as secondary.&#xD;
&#xD;
      Primary bruxism is a condition that is not well known to the general public, but I is very&#xD;
      widespread (12% of the adult population). In addition, it can alter quality of life, as a&#xD;
      result of associated sleep disorders, concentration disorders, daytime fatigue, chronic pain,&#xD;
      etc.&#xD;
&#xD;
      The current treatment for this condition is only symptomatic. Currently, one of the most&#xD;
      effective treatments is the intramuscular injection of botulinum toxin A in the muscles of&#xD;
      mastication. The progressive anticholinergic action results in a reduction of functional&#xD;
      signs (dental pain, periodontal pain, temporomandibular joint pain, tension headaches, neck&#xD;
      pain) and physical signs (reduction of the mass of the injected muscles, alba linea, tongue&#xD;
      scalloping, limitation or stability of dental damage).&#xD;
&#xD;
      However, these clinical data are practically not objectified in daily practice. Objective&#xD;
      criteria would make it possible to measure the effectiveness of the treatment, to follow the&#xD;
      patient, and to identify the early symptoms in order to prevent a recurrence.&#xD;
&#xD;
      The aim of the prospective study is to concretely measure the strength and electromyographic&#xD;
      activity of the muscles of mastication before and after botulinum toxin injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of episodes of nocturnal bruxism</measure>
    <time_frame>1 month after treatment by botulinum toxin injection</time_frame>
    <description>measurement of the number of bruxism episodes via a portable electromyogram we expect a significant improvement in the number of nocturnal bruxism episodes (decrease in relation to time 0)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bruxism</condition>
  <arm_group>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin injection</intervention_name>
    <description>Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QOL-Brux</intervention_name>
    <description>Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscular strength of the jaw</intervention_name>
    <description>Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.&#xD;
At inclusion and 1 month post-injection.</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensity and frequency of episodes of nocturnal bruxism</intervention_name>
    <description>Measurements via a portable electromyography system, coupled with a heartbeat sensor (BruxoffÂ®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>visual analogue pain scale</intervention_name>
    <description>Evaluation of jaw pain. At inclusion and 3 months post-injection</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endobuccal and linea alba photographs</intervention_name>
    <description>anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).&#xD;
At inclusion</description>
    <arm_group_label>Symptomatic patients in the context of bruxism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who has given written consent.&#xD;
&#xD;
          -  Patient between 18 and 64 years of age.&#xD;
&#xD;
          -  Patient who has never received botulinum toxins&#xD;
&#xD;
          -  Symptomatic patient in the context of bruxism in failure to the usual treatments&#xD;
             (analgesic, physiotherapy, relaxation technique and maxillary retainer)&#xD;
&#xD;
          -  Woman of childbearing age using an effective method of contraception&#xD;
&#xD;
          -  Symptomatic patients in the context of bruxism, without a maxillary disocclusion&#xD;
             retainer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected Adult&#xD;
&#xD;
          -  Patient not affiliated to the national health insurance system&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Refusal to take part in the study&#xD;
&#xD;
          -  Neuromuscular diseases, including Myasthenia gravis, Myopathies, Amyotrophic Lateral&#xD;
             Sclerosis. Lambert-Eaton Syndrome, patients with peripheral motor neuropathies,&#xD;
             patients with underlying neurological disorders.&#xD;
&#xD;
          -  Patients with a history of cardiovascular disease&#xD;
&#xD;
          -  Patients with epilepsy or a previous seizure episode&#xD;
&#xD;
          -  Neurogenic impairment of the face (including facial paralysis, polyradiculoneuritis)&#xD;
&#xD;
          -  History of dysphagia or pulmonary aspiration&#xD;
&#xD;
          -  Injection site infection (masseter and temporal)&#xD;
&#xD;
          -  Hypersensitivity or allergy to botulinum toxin or any of its excipients.&#xD;
&#xD;
          -  Treatment with aminoglycosides or anticholinesterase agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Narcisse ZWETYENGA</last_name>
    <phone>03 80 29 37 57</phone>
    <email>narcisse.zwetyenga@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Narcisse ZWETYENGA</last_name>
      <phone>03 80 29 37 57</phone>
      <email>narcisse.zwetyenga@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bruxism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

